POPULARITY
23 episodes with car t cell therapy
18 episodes with car t cell therapy
7 episodes with car t cell therapy
8 episodes with car t cell therapy
13 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
6 episodes with car t cell therapy
4 episodes with car t cell therapy
4 episodes with car t cell therapy
6 episodes with car t cell therapy
7 episodes with car t cell therapy
2 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
3 episodes with car t cell therapy
6 episodes with car t cell therapy
3 episodes with car t cell therapy
3 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
3 episodes with car t cell therapy
6 episodes with car t cell therapy
4 episodes with car t cell therapy
6 episodes with car t cell therapy
2 episodes with car t cell therapy
5 episodes with car t cell therapy
3 episodes with car t cell therapy
4 episodes with car t cell therapy
4 episodes with car t cell therapy
4 episodes with car t cell therapy
“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53
In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing resistance.
For decades, Dr. Bruce Levine has been at the forefront of cancer research, pioneering CAR T-cell therapy—a treatment that harnesses a patient’s own immune system to fight cancer. On a recent conversation with Asia Tabb, Levine shared his journey and the promise of this innovative therapy.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8009 Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/37272512/ Plain Language Summary of the KarMMa-3 Study of Ide-cel or Standard of Care Regimens in People With Relapsed or Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38651976/ CAR T-Cell Therapy Toxicity https://www.ncbi.nlm.nih.gov/books/NBK592426/ Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience https://pubmed.ncbi.nlm.nih.gov/28205024/ Incidence and Outcomes of Cytomegalovirus Reactivation After Chimeric Antigen Receptor T-Cell Therapy https://pubmed.ncbi.nlm.nih.gov/38838226/ Long-Acting Granulocyte Colony-Stimulating Factor in Primary Prophylaxis of Early Infection in Patients With Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35064823/ Revisiting the Role of Alkylating Agents in Multiple Myeloma: Up-to-Date Evidence and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/37244325/ Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma: Updates and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/38660139/ FDA Eliminates REMS for Approved CAR T-Cell Therapies https://www.aabb.org/news-resources/news/article/2025/06/30/fda-eliminates-rems-for-approved-car-t-cell-therapies
Featuring an interview with Dr Beth Faiman, including the following topics: Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00) Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19) Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00) Patient eligibility to receive CAR T-cell therapy (13:23) Differentiating among approved CAR T-cell therapies for MM (18:18) Durability of responses to CAR T-cell therapy for MM (24:01) Neurotoxicity with CAR T-cell therapies for MM (26:26) Minimal residual disease monitoring in MM (29:39) Support systems for the management of toxicities associated with CAR T-cell therapy (35:10) Patients with MM experiencing durable responses to CAR T-cell therapy (43:11) NCPD information and select publications
Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here.
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a promising blood test to distinguish Parkinson's disease from dementia with Lewy bodies, how CAR T-cell therapies are showing potential for patients with glioblastoma, and a new wireless electroencephalogram device that can even monitor young children with epilepsy.
In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.LymphomasDLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCTFL: Tisa-cel (ELARA), axi-cel (ZUMA-5)MZL: Liso-cel (TRANSCEND FL)MCL: Real-world outcomes post brexu-celCLL: Liso-cel (TRANSCEND CLL 004)Multiple MyelomaCilta-cel (CARTITUDE-1)Anito-cel (iMMagine-1)GC012FArlo-celBMS-986453TriPRIL Presenters:Brad Kahl, MDProfessor of MedicineWashington University St Louis, MissouriNoopur Raje, MD Director, Center for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, Massachusetts Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.Link to full program: https://bit.ly/3ViR62V
With Dr Larry Bacon, Consultant Haematologist from St James's Hospital, and Dr Nicola Gardiner, Chief Medical Scientist at the Cryobiology Laboratory Stem Cell Facility at St James's.Newsround with Dr Ruth Freeman from Research Ireland and science communicator Fergus McAuliffe.
In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia
Guest: Mateo Mejia Saldarriaga, M.D. Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days. © 2025 NewYork-Presbyterian
Send us a textThe future of cancer treatment is on the horizon, but can we afford it, regulate it, and deliver it at scale?In this episode of the HealthBiz Podcast, Dr. Jason Bock, Co-founder and CEO of CTMC, discusses the progress of CAR T cell therapy, the challenges of scaling manufacturing for personalized treatments, and how new payment and policy models can support broader access. He shares inspiring patient success stories, insights into the future of solid tumor therapies, and CTMC's mission to bring advanced therapies to more patients, faster.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Manali Kamdar, MD Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help improve patient access, a recent study explored exactly when toxicities occur and whether post-infusion monitoring could be shortened without compromising safety. And based on the findings, it's time to rethink the 4-week monitoring window. To learn more about the study's results and what they mean for patient monitoring, safety, and broader outcomes, tune in to hear Dr. Charles Turck speak with Dr. Manali Kamdar, who authored a poster on this topic that was presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Manali Kamdar, MD Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help improve patient access, a recent study explored exactly when toxicities occur and whether post-infusion monitoring could be shortened without compromising safety. And based on the findings, it's time to rethink the 4-week monitoring window. To learn more about the study's results and what they mean for patient monitoring, safety, and broader outcomes, tune in to hear Dr. Charles Turck speak with Dr. Manali Kamdar, who authored a poster on this topic that was presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24) Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53) Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51) Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22) Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55) CME information and select publications
In the second installment of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss clinical guidance for managing patients who may experience neurotoxicity from CAR T-cell, with a specific focus on seizure risk. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213535
In part one of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss the incidence of acute symptomatic seizures during CAR T-cell therapy. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213535
Dr. Jeff Ratliff talks with Dr. Brin E. Freund about the evaluated incidence and risk factors for acute symptomatic seizures during CAR T-cell therapy. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics: Introduction: ASCO 2025 Preview (0:00) Anti-CD38 Antibodies (10:12) Belantamab Mafodotin (29:45) CAR T-Cell Therapy (40:57) Bispecific Antibodies (47:33) Other Novel Agents (56:46) CME information and select publications
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications
Featuring perspectives from Dr Natalie S Callander and Dr Thomas Martin, including the following topics: Introduction (0:00) Current and Emerging Therapeutic Approaches for Multiple Myeloma — Dr Callander (4:42) CAR T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Martin (31:16) CME information and select publications
Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
Curious about CAR T-cell therapy? We went straight to the source for answers. In this episode, the LLS Patient Education… The post CAR T-cell Therapy: Your Questions Answered first appeared on The Bloodline with LLS.
Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.
Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics: Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00) Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42) Role of Venetoclax in the Treatment of CLL (26:52) AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29) Noncovalent BTK Inhibitor Pirtobrutinib (46:47) CAR T-Cell Therapy; Novel Agents (56:12) CME information and select publications
First, we talk to The Indian Express' Divya A about Ranjini Srinivasan, an Indian PhD scholar from Columbia University in the US, whose F-1 student visa was revoked for allegedly advocating for violence and terrorism and supporting Hamas. Fearing action by the authorities, she chose to self-deport and return home.Next, The Indian Express' Anonna Dutt talks about CAR T- cell therapy or chimeric antigen receptor T-cell therapy, which is a novel treatment method for cancer. She shares how the clinical trial results of India's CAR T-cell therapy were published in the Lancet and more. (11:24)Lastly, we speak about Israel's biggest assault on the Gaza Strip since the ceasefire on 19th January. (19:28)Produced and hosted by Niharika Nanda and Shashank BhargavaEdited and mixed by Suresh Pawar
Featuring an interview with Dr Surbhi Sidana, including the following topics: Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00) Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34) Practical challenges for patients receiving CAR T-cell therapy (8:34) Selection among available CAR T-cell therapies (12:18) Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34) Secondary cancers associated with CAR T-cell therapy (21:25) Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15) Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49) Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59) Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47) CME information and select publications
Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. CME information and select publications here.
Featuring a slide presentation and related discussion from Dr Surbhi Sidana, including the following topics: Key clinical data of FDA-approved chimeric antigen receptor (CAR) T-cell therapies (0:00) Real-world evidence evaluating utility of CAR T-cell therapies in the clinic (8:08) Impact of prior BCMA-targeted treatment on CAR T-cell therapy efficacy (12:55) Investigational CAR T-cell therapies in clinical development (15:08) Incidence and management of toxicities associated with CAR T-cell therapy (18:21) CME information and select publications
Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. CME information and select publications here.
Drs Dahiya and Patel discussed the pathobiology of SPCs that develop after CAR T-cell therapy, potential SPC prevention strategies, and how SPC research may help optimize CAR T-cell product development in the future.
Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SOHO2024/CARTCell/Video).
Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications
Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL). We dived into three key studies: 1. SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy. 2. AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S. 3. Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor. Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment. Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions! Subscribe to stay updated on the latest in oncology research and treatments! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
In a Chinese study, donor CAR-T cells sent autoimmune diseases into remission. There's hope that the therapy is scalable. And, scientists used decades of yellow-bellied marmot research to find a way to measure how adverse events affect wild animals' survival.CAR-T Cell Therapies Show Promise For Autoimmune DiseasesFor decades, immunologists have explored CAR-T cell therapy as an effective tool to fight blood cancer. Increasingly, CAR-T cells are being explored as a potential silver bullet for treating autoimmune diseases, like lupus—which currently have no cure.Thus far, CAR-T cell therapy has largely used CRISPR-modified immune cells from a person to treat that person's own diseases. But new research from China has made a huge step forward for this treatment: Researchers were successful in using donated CAR-T cells from one person to treat another person's systemic sclerosis, an autoimmune condition that causes atypical growth of connective tissues.If donor CAR-T cell therapy does indeed work, as posited in this paper, it could mean the therapy is more scalable than it would be otherwise. Joining Ira to talk about this study and its potential impact is Daniel Baker, PhD student in the immunology lab of Dr. Carl June at the University of Pennsylvania.Measuring The Effects Of Early Life Adversity—In MarmotsIt's well-established in psychology that if you experience trauma as a child, chances are it'll impact your physical and mental health as an adult, and could even affect your economic status. In academic terms, this is called early childhood adversity. And psychologists have developed a scoring system for measuring the cumulative effect of adverse childhood experiences, which can include abuse and household dysfunction, and it can help predict health risks later in life.So we can specifically measure that in humans. But what about other animals? If you've adopted a dog that's had a turbulent past, you know that that can result in reclusive or skittish behavior as an adult. But there hasn't been a good way to measure it in wild animals.Well, a new study from UCLA, published in the journal Ecology Letters, establishes a similar index for wild animals, and it used decades of findings from a mammal: the yellow-bellied marmot. So how could it help conservation efforts for other animals?Ira Flatow talks with Xochitl Ortiz-Ross, a PhD student in ecology and evolutionary biology at UCLA, and one of the authors on that study.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
© 2020-2025 Ivy Podcast Discovery LLC
